NCCN task force report: mTOR inhibition in solid tumors

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan, Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, Yun Yen

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving cell cycle progression, proliferation, and angiogenesis. These pathways are frequently dysregulated in cancer, and therefore mTOR inhibition is a potentially important antitumor target. Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus. Other agents under investigation include everolimus and deforolimus. mTOR inhibition has been studied in various solid tumors, including breast, gynecologic, gastrointestinal, prostate, lung, and head and neck cancers. Studies have focused on mTOR inhibition as a monotherapy or in combination with other drugs based on the principle that inhibiting as many targets as possible reduces the emergence of drug resistance. Temsirolimus is currently the only mTOR inhibitor that is specifically labeled for treatment of solid tumors. However, preclinical studies and early-phase trials are rapidly evolving. Additionally, research is further defining the complicated mTOR pathways and how they may be disordered in specific malignancies. To address these issues, NCCN convened a task force to review the underlying physiology of mTOR and related cellular pathways, and to review the current status of research of mTOR inhibition in solid tumors.

Original languageEnglish
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue numberSUPPL. 5
Publication statusPublished - Oct 9 2008
Externally publishedYes

Fingerprint

Advisory Committees
Sirolimus
Neoplasms
TOR Serine-Threonine Kinases
Head and Neck Neoplasms
Research
Drug Resistance
Prostate
Lung Neoplasms
Cell Cycle
Breast Neoplasms

Keywords

  • Cancer
  • Deforolimus
  • Everolimus
  • Malignancy
  • mTOR
  • mTOR inhibition
  • NCCN Clinical Practice Guidelines
  • Rapamycin
  • Targeted therapy
  • Temsirolimus

ASJC Scopus subject areas

  • Oncology

Cite this

Figlin, R. A., Brown, E., Armstrong, A. J., Akerley, W., Benson, A. B., Burstein, H. J., ... Yen, Y. (2008). NCCN task force report: mTOR inhibition in solid tumors. JNCCN Journal of the National Comprehensive Cancer Network, 6(SUPPL. 5).

NCCN task force report : mTOR inhibition in solid tumors. / Figlin, Robert A.; Brown, Elizabeth; Armstrong, Andrew J.; Akerley, Wallace; Benson, Al B.; Burstein, Harold J.; Ettinger, David S.; Febbo, Phillip G.; Fury, Matthew G.; Hudes, Gary R.; Kies, Merrill S.; Kwak, Eunice L.; Morgan, Robert J.; Mortimer, Joanne; Reckamp, Karen; Venook, Alan P.; Worden, Frank; Yen, Yun.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. SUPPL. 5, 09.10.2008.

Research output: Contribution to journalArticle

Figlin, RA, Brown, E, Armstrong, AJ, Akerley, W, Benson, AB, Burstein, HJ, Ettinger, DS, Febbo, PG, Fury, MG, Hudes, GR, Kies, MS, Kwak, EL, Morgan, RJ, Mortimer, J, Reckamp, K, Venook, AP, Worden, F & Yen, Y 2008, 'NCCN task force report: mTOR inhibition in solid tumors', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. SUPPL. 5.
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ et al. NCCN task force report: mTOR inhibition in solid tumors. JNCCN Journal of the National Comprehensive Cancer Network. 2008 Oct 9;6(SUPPL. 5).
Figlin, Robert A. ; Brown, Elizabeth ; Armstrong, Andrew J. ; Akerley, Wallace ; Benson, Al B. ; Burstein, Harold J. ; Ettinger, David S. ; Febbo, Phillip G. ; Fury, Matthew G. ; Hudes, Gary R. ; Kies, Merrill S. ; Kwak, Eunice L. ; Morgan, Robert J. ; Mortimer, Joanne ; Reckamp, Karen ; Venook, Alan P. ; Worden, Frank ; Yen, Yun. / NCCN task force report : mTOR inhibition in solid tumors. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. SUPPL. 5.
@article{ce8587a93bfe47eba1637789eba37e8d,
title = "NCCN task force report: mTOR inhibition in solid tumors",
abstract = "The mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving cell cycle progression, proliferation, and angiogenesis. These pathways are frequently dysregulated in cancer, and therefore mTOR inhibition is a potentially important antitumor target. Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus. Other agents under investigation include everolimus and deforolimus. mTOR inhibition has been studied in various solid tumors, including breast, gynecologic, gastrointestinal, prostate, lung, and head and neck cancers. Studies have focused on mTOR inhibition as a monotherapy or in combination with other drugs based on the principle that inhibiting as many targets as possible reduces the emergence of drug resistance. Temsirolimus is currently the only mTOR inhibitor that is specifically labeled for treatment of solid tumors. However, preclinical studies and early-phase trials are rapidly evolving. Additionally, research is further defining the complicated mTOR pathways and how they may be disordered in specific malignancies. To address these issues, NCCN convened a task force to review the underlying physiology of mTOR and related cellular pathways, and to review the current status of research of mTOR inhibition in solid tumors.",
keywords = "Cancer, Deforolimus, Everolimus, Malignancy, mTOR, mTOR inhibition, NCCN Clinical Practice Guidelines, Rapamycin, Targeted therapy, Temsirolimus",
author = "Figlin, {Robert A.} and Elizabeth Brown and Armstrong, {Andrew J.} and Wallace Akerley and Benson, {Al B.} and Burstein, {Harold J.} and Ettinger, {David S.} and Febbo, {Phillip G.} and Fury, {Matthew G.} and Hudes, {Gary R.} and Kies, {Merrill S.} and Kwak, {Eunice L.} and Morgan, {Robert J.} and Joanne Mortimer and Karen Reckamp and Venook, {Alan P.} and Frank Worden and Yun Yen",
year = "2008",
month = "10",
day = "9",
language = "English",
volume = "6",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "SUPPL. 5",

}

TY - JOUR

T1 - NCCN task force report

T2 - mTOR inhibition in solid tumors

AU - Figlin, Robert A.

AU - Brown, Elizabeth

AU - Armstrong, Andrew J.

AU - Akerley, Wallace

AU - Benson, Al B.

AU - Burstein, Harold J.

AU - Ettinger, David S.

AU - Febbo, Phillip G.

AU - Fury, Matthew G.

AU - Hudes, Gary R.

AU - Kies, Merrill S.

AU - Kwak, Eunice L.

AU - Morgan, Robert J.

AU - Mortimer, Joanne

AU - Reckamp, Karen

AU - Venook, Alan P.

AU - Worden, Frank

AU - Yen, Yun

PY - 2008/10/9

Y1 - 2008/10/9

N2 - The mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving cell cycle progression, proliferation, and angiogenesis. These pathways are frequently dysregulated in cancer, and therefore mTOR inhibition is a potentially important antitumor target. Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus. Other agents under investigation include everolimus and deforolimus. mTOR inhibition has been studied in various solid tumors, including breast, gynecologic, gastrointestinal, prostate, lung, and head and neck cancers. Studies have focused on mTOR inhibition as a monotherapy or in combination with other drugs based on the principle that inhibiting as many targets as possible reduces the emergence of drug resistance. Temsirolimus is currently the only mTOR inhibitor that is specifically labeled for treatment of solid tumors. However, preclinical studies and early-phase trials are rapidly evolving. Additionally, research is further defining the complicated mTOR pathways and how they may be disordered in specific malignancies. To address these issues, NCCN convened a task force to review the underlying physiology of mTOR and related cellular pathways, and to review the current status of research of mTOR inhibition in solid tumors.

AB - The mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving cell cycle progression, proliferation, and angiogenesis. These pathways are frequently dysregulated in cancer, and therefore mTOR inhibition is a potentially important antitumor target. Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus. Other agents under investigation include everolimus and deforolimus. mTOR inhibition has been studied in various solid tumors, including breast, gynecologic, gastrointestinal, prostate, lung, and head and neck cancers. Studies have focused on mTOR inhibition as a monotherapy or in combination with other drugs based on the principle that inhibiting as many targets as possible reduces the emergence of drug resistance. Temsirolimus is currently the only mTOR inhibitor that is specifically labeled for treatment of solid tumors. However, preclinical studies and early-phase trials are rapidly evolving. Additionally, research is further defining the complicated mTOR pathways and how they may be disordered in specific malignancies. To address these issues, NCCN convened a task force to review the underlying physiology of mTOR and related cellular pathways, and to review the current status of research of mTOR inhibition in solid tumors.

KW - Cancer

KW - Deforolimus

KW - Everolimus

KW - Malignancy

KW - mTOR

KW - mTOR inhibition

KW - NCCN Clinical Practice Guidelines

KW - Rapamycin

KW - Targeted therapy

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=54749149761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749149761&partnerID=8YFLogxK

M3 - Article

C2 - 18926092

AN - SCOPUS:54749149761

VL - 6

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - SUPPL. 5

ER -